Efficacy and safety of tafasitamab and lenalidomide (TAFA_LEN) in combination with the R-CHOP regimen for the treatment of newly diagnosed intermediate-high-risk diffuse large B-cell lymphoma (ChiCTR) - Oct 16, 2026 - P4 | N=48 | Not yet recruiting | Sponsor: The second affiliated hospital of Zhejiang University school of medicine; The second affiliated hospital of Zhejiang University school of medicine
New P4 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|